Scinai Immunotherapeutics Ltd. has acquired Recipharm Israel Ltd., operator of Recipharm’s manufacturing site in Yavne, and signed a long‑term commercial collaboration with Recipharm aimed at expanding its contract development and manufacturing (CDMO) operations.

The deal gives Scinai full ownership of the Yavne cGMP facility, which provides early chemistry development and small‑scale API manufacturing for clinical‑stage drug programs. Financial terms weren’t disclosed. Scinai said the transaction was structured as a share purchase to ensure operational continuity, including retention of staff, regulatory approvals, and customer contracts.

The Yavne site will be integrated into Scinai’s existing CDMO platform alongside its Jerusalem operations, broadening the company’s capabilities across recombinant proteins, small molecules, peptides, antibodies and oligonucleotides.

As part of the collaboration agreement, Scinai will serve as a preferred partner for early‑stage development work for projects within Recipharm’s network, while Recipharm will act as a preferred provider for late‑stage and commercial manufacturing for Scinai’s clients, subject to capacity and technical fit. The companies plan to establish quality and tech‑transfer frameworks to streamline movement of client programs between facilities.

Scinai said the arrangement is intended to create an end‑to‑end service offering that reduces friction as programs transition from early development to global commercial manufacturing. The companies will also share economics on projects that advance to later‑stage supply at Recipharm sites.

Scinai expects the acquisition and partnership to strengthen its competitive position by expanding service breadth, improving handling of complex and hazardous materials, and providing access to Recipharm’s global manufacturing network for programs that exceed Scinai’s internal capacity.

“This transaction fundamentally strengthens Scinai’s CDMO platform,” said Amir Reichman, CEO of Scinai. “By combining our early-stage development strengths with Recipharm Israel’s manufacturing capabilities and Recipharm’s global footprint, we are creating a differentiated offering that supports clients from early development through commercialization. Importantly, the collaboration allows Scinai to participate in the long-term success of client programs while maintaining capital discipline and operational focus.”

“Ensuring continuity for the Yavne site, its employees and its customers was a key priority for us, and we are pleased to pair that with a strategic collaboration with Scinai,” said Greg Behar, CEO of Recipharm. “The agreement creates a clear pathway for programs to progress efficiently into Recipharm’s global development and commercial manufacturing network.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.